Whereas both GABA A receptors (GABA A Rs) and glycine receptors (GlyRs) play a role in control of dorsal horn neuron excitability, their relative contribution to inhibition of small diameter primary afferent terminals remains controversial. To address this, we designed an approach for quantitative analyses of the distribution of GABA A R-subunits, GlyR ␣1-subunit and their anchoring protein, gephyrin, on terminals of rat spinal sensory afferents identified by Calcitonin-Gene-Related-Peptide (CGRP) for peptidergic terminals, and by Isolectin-B4 (IB4) for nonpeptidergic terminals. The approach was designed for light microscopy, which is compatible with the mild fixation conditions necessary for immunodetection of several of these antigens. An algorithm was designed to recognize structures with dimensions similar to those of the microscope resolution. To avoid detecting false colocalization, the latter was considered significant only if the degree of pixel overlap exceeded that expected from randomly overlapping pixels given a hypergeometric distribution. We found that both CGRP ϩ and IB4 ϩ terminals were devoid of GlyR ␣1-subunit and gephyrin. The ␣1 GABA A R was also absent from these terminals. In contrast, the GABA A R ␣2/␣3/␣5 and ␤3 subunits were significantly expressed in both terminal types, as were other GABA A R-associated-proteins (␣-Dystroglycan/Neuroligin-2/Collybistin-2). Ultrastructural immunocytochemistry confirmed the presence of GABA A R ␤3 subunits in small afferent terminals. Real-time quantitative PCR (qRT-PCR) confirmed the results of light microscopy immunochemical analysis. These results indicate that dorsal horn inhibitory synapses follow different rules of organization at presynaptic versus postsynapticsites(nociceptiveafferentterminalsvsinhibitorysynapsesondorsalhornneurons).Theabsenceofgephyrinclustersfromprimary afferent terminals suggests a more diffuse mode of GABA A -mediated transmission at presynaptic than at postsynaptic sites.
Introduction
Pain-related information transmitted from the periphery to the brain is regulated by ionotropic inhibition at the first afferent synapses in the spinal dorsal horn. Intrathecal administration of strychnine and bicuculline in the adult rat can replicate symptoms characteristic of neuropathic pain (Yaksh, 1989; Sherman and Loomis, 1994; Sorkin et al., 1998; Ren and Dubner, 2008) , identifying GABA A receptors (GABA A Rs) and glycine receptors (GlyRs) as key regulators of spinal nociceptive output. Furthermore, in experimental models of neuropathic pain, hypersensitivity can be reversed through activation of specific spinal GABA A R subtypes (Knabl et al., 2008; Paul et al., 2014) and part of this GABAergic action appears to be mediated by a direct presynaptic inhibition of small diameter primary afferent terminals through the GABA A R ␣2 subunit (Witschi et al., 2011) . However, the details of the synaptic arrangement of GABA A Rs/GlyRs and their anchoring protein gephyrin on these terminals remain elusive (Bardoni et al., 2013) . Even less is known regarding a possible involvement of GlyRs in presynaptic control of small diameter afferents in the dorsal horn. Whereas functional evidence of presynaptic glycinergic control is lacking (Eccles et al., 1963; Jiménez et al., 1987; Maxwell and Riddell, 1999; Willis, 2006) , past reports have described the expression of some GlyR subunits in the dorsal root ganglion (DRG) (Furuyama et al., 1992) , suggesting that they may play a role in controlling afferent terminal excitability (Dutertre et al., 2012) .
To address these issues, we conducted a quantitative analysis of the distribution of GABA A R ␣1/␣2/␣3/␣5 and ␤3 subunits, the GlyR ␣1 subunit, and several proteins associated with inhibitory synapses[gephyrin/␣-Dystroglycan(␣-DG)/Neuroligin-2(NL2)/ Collybistin-2 (CB2)] in small diameter afferent terminals identified by calcitonin-gene-related-peptide (CGRP) immunoreactivity and binding of the isolectin-B4 (IB4). We performed light and electron microscopy immunohistochemical analyses of multiple signals. We mildly fixed the tissue slices to maximize antigen detection and to minimize false-negative detection of certain proteins in subcellular compartments. We also designed a signal detection protocol to identify structures with dimensions close to the resolution limits [point spread function (PSF)] of the laser scanning confocal system we used and to avoid biases from arbitrarily choosing intensity thresholds. Finally, we designed a quantitative analysis protocol to avoid false-positive detection of colocalization at the light microscopy level. We then performed ultrastructural analyses of the distribution of subunits for which a normal fixation protocol had little impact on detection. Finally, we analyzed mRNA expression for each of the proteins under study in primary afferent versus dorsal horn compartments.
We found that both the GlyR ␣1 subunit and the anchoring protein gephyrin Tretter et al., 2012; Tyagarajan and Fritschy, 2014) were absent from small diameter primary afferent terminals. In addition, GABA A R subtypes followed a specific expression pattern; there was a lack of the presynaptic GABA A R ␣1 subunit and a preferential distribution of the GABA A R ␣2 subunit on primary afferent terminals. In contrast to the lack of presynaptic gephyrin, we found other GABA A Rassociated proteins (␣-DG/NL2/CB2) in small diameter primary afferents, suggesting gephyrin-free presynaptic inhibitory arrangements. The lack of gephyrin clusters on primary afferent terminals suggests a more diffuse mode of GABA A -mediated transmission at presynaptic sites.
Materials and Methods

Animals
The present study was performed in young adult male Sprague Dawley rats weighting 200 -225 g (Charles River Laboratories). All experimental procedures were performed in accordance with the Care and Use of Experimental Animals from the Canadian Council on Animal Care and all experimental procedures were approved by the McGill and Laval Universities Animal Care Committees. A total of 61 rats were used in this study. Forty-four rats were processed with a mild fixation tissue protocol, six rats were processed with a regular perfusion fixation protocol, four rats were used for electron microscopy, and seven rats were used for qRT-PCR.
Antibodies and markers
Anti-GABA A R subtype-specific antibodies. The antibodies raised against the ␣-GABA A R subtypes used in this study were generously provided by Dr. Jean-Marc Fritschy. These primary polyclonal antibodies were raised against synthetic peptide sequences derived from the GABA A R ␣1, ␣2, ␣3, and ␣5 subunit cDNAs and coupled to KLH (Fritschy and Möhler, 1995) . The following peptide sequences were used: ␣1 subunit residues 1-16, ␣2 subunit residues 1-9, ␣3 subunit residues 1-15, and ␣5 subunit residues 1-29. All of these antibodies were raised in guinea pigs. The dilutions of the antibodies were as follows: ␣1 subunit, 1:20,000; ␣2 subunit, 1:10,000; ␣3 subunit, 1:10,000; and ␣5 subunit, 1:4000. Immunocytochemical characterization of these antibodies has been described previously Benke et al., 1996) . Their specificity has been evidenced by using mutant mice lacking the ␣1, ␣2, ␣3, and ␣5 subunit genes. Immunocytochemistry showed a complete absence of immunolabeling of the GABA A ␣1, ␣2, ␣3, and ␣5 subunits in ␣1, ␣2, ␣3, and ␣5 KO mice . These antibodies have also been well characterized and used immunohistochemically in human tissues, including spinal cord (Bohlhalter et al., 1994; Bohlhalter et al., 1996; Waldvogel et al., 2010; Paul et al., 2012) . The anti-GABA A R ␤3 subunit antibodies were graciously provided by Dr. Werner Sieghart (antibody raised in rabbit) or by Dr. Ryuichi Shigemoto (antibody raised in guinea pig). They were both used, and provided identical results. For more details, see Kasugai et al., 2010 . These two antibodies were raised against maltose-binding protein and aa 345-408 of the rat ␤3 subunit, part of the large intracellular loop between putative transmembrane domains M3 and M4. Antibodies were isolated by chromatography on a fusion protein consisting of glutathione S-transferase, amino acids 345-408 of the ␤3 subunit, and seven histidines (Tögel et al., 1994; Slany et al., 1995; Kasugai et al., 2010) .
GABA A R-associated protein antibodies. To identify ␣-DG, a monoclonal antibody was used (clone IIH6C4, catalog #05-593; Millipore). This antibody targets a functional carbohydrate epitope on ␣-DG (Gee et al., 1994; Goddeeris et al., 2013) , added in part by the glycosyltransferase LARGE and is essential for ligand binding (Leschziner et al., 2000; Goddeeris et al., 2013) . The IIH6 antibody is highly specific for ␣-DG (Ervasti and Campbell, 1993; Jacobson et al., 1998; Moore et al., 2002) . To detect NL2, an affinity-purified rabbit antibody was used (catalog #129203; Synaptic Systems). This affinity-purified antibody was raised against a synthetic peptide of rat NL2 (aa 732-749) coupled to KLH via an added C-terminal cysteine residue. The antibody is highly specific for NL2 and does not display any cross-reactivity with NL1, NL3, or NL4 (information provided by Synaptic Systems). To reveal CB2, we used an affinitypurified rabbit antibody (catalog #261003; Synaptic Systems). This antibody was raised against aa 4 -229 of rat CB. This antibody is highly specific and only recognizes the three described splice variants of CB2 (information provided by Synaptic Systems).
Anti-glycine receptor ␣1 subunit and anti-gephyrin antibodies. The GlyR ␣1 subunit was detected with a monoclonal antibody (mAb2b, mouse, 1:500, catalog #146111; Synaptic Systems; Pfeiffer et al., 1982; Pfeiffer et al., 1984; Schröder et al., 1991; Baer et al., 2003) . This monoclonal antibody was raised against a peptide coupled to KLH corresponding to N-terminal residues 1-10 of the human ␣1 subunit (Durisic et al., 2012) and showed a single band of 48 kDa on Western blot (data supplied by Synaptic Systems). A mouse monoclonal antibody (Pfeiffer et al., 1984; Kirsch and Betz, 1998) raised against purified rat gephyrin was used in this study (mAb7a, 1:500, catalog #147011 and catalog #147011C3 for the mAb7a gephyrin-Oyster for double staining with the anti-GlyR mAb2b monoclonal antibody; Synaptic Systems). The antigephyrin mAb7a antibody is highly specific for immunohistochemical investigations of gephyrin, as documented by several studies using light and electron microscopy (Kneussel et al., 1999; Lorenzo et al., 2004; Schneider Gasser et al., 2006; Mukherjee et al., 2011) , and as shown by the complete absence of staining in gephyrin KO mice (Feng et al., 1998; Kneussel et al., 1999; Fischer et al., 2000) . This antibody does not interfere with any of the isolated domains of gephyrin involved in its own clustering nor with the GlyR and GABA A R clustering at inhibitory postsynaptic sites (LardiStudler et al., 2007) . Because gephyrin immunolabeling identifies a protein associated with the postsynaptic membrane at inhibitory synapses, its colocalization with receptor subunits was used as a marker of the synaptic location of these receptor subunits (Lorenzo et al., 2004) .
Markers of small diameter afferent terminals. CGRP immunoreactivity was used as a specific marker of peptidergic primary afferent terminals because it is not present in any other types of axons in the dorsal horn (Rosenfeld et al., 1983; Gibson et al., 1984; Hunt and Rossi, 1985; Ju et al., 1987) . The anti-CGRP antibody (1:2000, catalog #C8198; Sigma) was raised in rabbit using synthetic rat CGRP conjugated to KLH as the immunogen. This antibody specifically recognizes the CGRP C-terminal segment (aa 24 -37) of rat CGRP. This antiserum shows no crossreactivity with any other peptide except human CGRP and rat and human ␤-CGRP (data supplied by Sigma); staining was completely abolished when the antiserum was preabsorbed with rat CGRP (data supplied by Sigma). IB4 binding has been used as a marker of a subset of small diameter primary afferents, including all of the nonpeptidergic nociceptive terminals (Sugiura, 1989; Rice, 1993; Alvarez and Fyffe, 2000; Ribeiro-da-Silva, 2004; Fang et al., 2006) . However, it should be noted that, in the rat, a small subset of primary afferents both express CGRP and bind IB4 (Priestley et al., 2002) . IB4 conjugated to Alexa Fluor 488 (1:200, catalog #I21411; Invitrogen) was used in this study to label nonpeptidergic C-terminals.
Markers of inhibitory terminals. A monoclonal mouse anti-Glutamate Acid Decarboxylase 65 (GAD65) antibody (1:1000, catalog #MAB351; Millipore) was used in this study. This antibody is an IgG2a raised against purified rat brain GAD as an immunogen; it has been tested in rat CNS and human brain and staining was absent in the presence of the immunogen (data supplied by Millipore).
Anti-KCC2 antibody. A polyclonal antibody raised in rabbit (catalog #07-432; Millipore) was used in this study. This antibody was raised against an N-terminal His-tag fusion protein corresponding to aa 932-1043 of the rat KCC2 intracellular C terminus (Williams et al., 1999; Mercado et al., 2006) . This antibody is highly specific for rat KCC2, recognizes the KCC2a and KCC2b isoforms, and does not show any sequence homology with other KCCs or cotransporters.
Control for possible antibody cross-reactivities. Control experiments for possible antibody cross-reactivities were run by simply omitting, in a systematic manner, one of the primary antibodies in the double-or triple-staining combinations. This allowed us to exclude crossreactivities in the multiple labeling experiments.
Secondary antibodies. The secondary antibodies and other related reagents used in this study are listed in Tables 1 and 2 .
Tissue processing and immunocytochemistry
Two main protocols of fixation were tested for all types of markers used in this study (see Mild fixation protocol and Perfusion fixation protocol, below). Classically, immunolabeling of proteins from excised CNS tissue is performed after vascular perfusion of the animal with 4% paraformaldehyde (PFA) in phosphate buffer (PB) and 2 h of immersion in the same fixative. However, GABA A R, GlyR, and gephyrin require a low PFA concentration fixation on fresh frozen tissue samples, as described previously (Schneider Gasser et al., 2006; . This mild fixation protocol has been used previously by L.-E.L. in recent publications (Lorenzo et al., 2006; Lorenzo et al., 2007) . In the present study, we combined this technique of immunolabeling with the syringe expulsion of fresh spinal cord. The use of these combined techniques made it possible to perform immunostainings on fresh after fixed L4-L5 lumbar segments of the spinal cord, in which most of the sciatic nerve afferents terminate.
Mild fixation protocol
Thirty-eight rats were anesthetized by isoflurane inhalation in an induction chamber and quickly killed by decapitation. A skin incision was made along the back of the animal. A 10 ml syringe equipped with an 18 Ga needle was filled previously with cold PBS. The extraction consisted of inserting the needle in the spinal canal at the L6-S1 level and then ejecting the whole spinal cord by a strong flow of cold PBS through the spinal canal. The spinal cord extracted in this way was immediately frozen in powdered dry ice for 1 min. The L4-L5 spinal cord segments were separated from the whole spinal cord with a cold razor blade. To keep the tissue frozen and to avoid any protein denaturation, the spinal cord segments were manipulated with cold forceps on a very cold Petri dish placed upside-down on dry ice; then, the L4-L5 spinal cord segments were placed in precooled 2 ml plastic tubes, which were stored in a Ϫ80°C freezer until further tissue processing.
Transverse, 14-m-thick sections were cut from the frozen spinal cord with a cryostat (CM 3050S; Leica) and mounted onto gelatinin-subbed slides (Fisherbrand). They were then immersed for 10 min in freshly depolymerized 4% PFA in 0.1 M sodium PB (0.1 M), pH 7.4, and rinsed in PBS (0.01 M; 3 ϫ 10 min). Sections were incubated for 12 h at 4°C in primary antibody mixtures diluted in PBS containing 4% normal donkey serum. Triton X-100 was never added to the solutions. After washing (3 ϫ 10 min), the sections were immersed in a solution containing a mixture of the appropriate fluorochrome-conjugated secondary antibodies diluted in PBS, pH 7.4, containing 4% normal donkey serum (catalog # 017-000-121; Jackson Immunoresearch) for 1 h at room temperature; then, sections were quickly immersed in distilled water and coverslipped using Aquapolymount (Polysciences).
Perfusion fixation protocol
Six Wistar rats were anesthetized with Equithesin (6.5 mg of chloral hydrate and 3 mg of sodium pentobarbital in a volume of 0.3 ml, i.p., per 100 g body weight). Animals were perfused transcardially with 4% PFA in 0.1 M PB, pH 7.4, for 30 min. Spinal cord segments L4-L5 were collected, postfixed for 2 h in the same fixative, and cryoprotected by immersion in 30% sucrose in 0.1 M PB overnight at 4°C.
Transverse sections were cut at 30 m on a sledge freezing microtome (SM2000R; Leica). Sections were collected into tissue culture plates with 24 wells, washed in PBS, pH 7.4, with 0.2% Triton (PBSϩT) for 10 min, and washed twice in PBS (5 min each). The sections were then incubated for 12 h at 4°C in primary antibody mixtures diluted in PBSϩT containing 4% normal donkey serum. After washing in PBS, the tissue was incubated for 2 h at room temperature in a solution containing a mixture of appropriate fluorochrome-conjugated secondary antibodies, diluted in PBSϩT, pH 7.4, containing 4% normal donkey serum. Last, sections were washed for 15 min (3 ϫ 5 min) with PBS, mounted on gelatinsubbed slides (Fisherbrand), allowed to dry overnight at 4°C, and coverslipped using Aquapolymount (Polysciences). 
Electron microscopy
Four rats were anesthetized with Equithesin and perfused transcardially with a mixture of 4% PFA, 15% picric acid, and 0.1% glutaraldehyde in 0.1 M PB, pH 7.4, for 30 min, followed by the same mixture without glutaraldehyde for 30 min and then for 30 min with a solution of 10% sucrose in 0.1 M PB, pH 7.4. Spinal cord segments L4-L5 were collected and placed in 30% sucrose in 0.1 M PB overnight at 4°C. Subsequently, spinal cord segments were snap-frozen by immersion in liquid nitrogen, thawed in 0.1 M PB at room temperature, and cut into 50-m-thick transverse sections with a Vibratome 1000 Plus (TPI). Sections were then incubated for 30 min in 1% sodium borohydride. After extensive washing (5 ϫ 12 min) in PBS, sections were incubated in 0.5% BSA in PBS for 30 min and then in 5% normal goat serum (Invitrogen) for 30 min. Sections were then incubated at 4°C for 48 h in the mouse anti-GAD65 monoclonal antibody (1:1000, catalog #MAB351; Millipore) and the same polyclonal rabbit anti-␤3 GABA A R antibody (1:100) from Dr. Werner Sieghart (Medical University of Vienna, Vienna, Austria) used for confocal microscopy diluted in PBS with 0.1% BSA. Then, sections were washed in PBS (2 ϫ 15 min) and incubated for 2 h in goat anti-mouse IgG (1:50; Table 2 ). Sections were then washed again in PBS (2 ϫ 15 min) and incubated for 12 h at 4°C in a mouse anti-horseradish peroxidase (HRP) monoclonal antibody (1:30; Medimabs; Semenenko et al., 1985) . After 2 ϫ 15 min washes, sections were incubated in HRP (5 g ml Ϫ1 , type VI, catalog #P8375; Sigma ) for 2 h. Sections were washed in PBS (3 ϫ 10 min) and the GAD65 antigenic sites were revealed by reacting the sections for 10 min at room temperature in 0.05% 3-3Јdiaminobenzidine tetrahydrochloride (DAB) with cobalt chloride and nickel ammonium sulfate, and then in the presence of 0.01% H 2 O 2 (for details, see Ribeiroda-Silva et al., 1993) . The reaction was stopped by washing in PBS (3 ϫ 10 min). Th sections were washed in 0.1% fish skin gelatin and 0.8% BSA in PBS (2 ϫ 5 min) and then incubated in goat anti-rabbit IgG conjugated to 1 nm gold particles (1:200; Biocell) for 12 h at 4°C to label the GABA A receptor ␤3 subunit. Sections were washed and incubated in 2% glutaraldehyde in PBS for 10 min, washed in PBS (3 ϫ 5 min), rinsed in distilled water (2 min), and washed in citrate buffer (3 ϫ 5 min). Silver intensification of the gold particles was performed for 17 min using a silver enhancement kit (GE Healthcare). Sections were rinsed twice in deionized water, rinsed for 5 min in PB, and incubated in 1% osmium tetroxide (OsO 4 ) in PB. Finally, the sections were dehydrated through ascending ethanol concentrations and propylene oxide. Sections were then flat embedded in Epon (for details, see Ribeiro-da-Silva et al., 1993) . The regions of interest (ROIs) were selected using light microscopy and reembedded in Epon blocks. Ultrathin sections were cut with a Reichert ultramicrotome and collected on Formvar-coated one-slot copper grids. The sections were counterstained with uranyl acetate and lead citrate before observation on a Philips 410 LS electron microscope equipped with a Megaview II digital camera.
Confocal image segmentation and colocalization measurements
All confocal images were acquired using an Olympus Fluoview FV1000 confocal laser scanning microscope (CLSM). Confocal acquisitions were 12 bit images with a 2048 ϫ 2048 pixel resolution and a 12.5 s laser time of scanning per pixel. Laser power was chosen to avoid saturation. All confocal observations were performed with the same laser settings (laser power, PMT settings, image, and pixel sizes). To study the distribution of receptors in primary afferent terminals in the spinal cord (with Matlab 2010a), the first step of the quantification was to define specific regions in an image acquired with the CLSM. The fluorescent stainings were studied in specific regions by image binarization for CGRP ϩ and IB4 ϩ sensory fiber terminals, inhibitory postsynaptic sites (gephyrin), and for receptor clusters (of GlyR and GABA A R subunits). The primary afferent component was defined using an object-base method (Otsu, 1979) . The diameter of fine dendrites and axonic profiles in CLSM images are of the order of the PSF. For this reason, the algorithm was made to recognize structures of a disc shape with dimensions similar to that of the PSF. The disc shape filter was applied to the images to amplify structures with similar shapes and, because of this, the resulting mask was independent of lowfrequency variations of diffuse signal in different spatial regions and the analysis was not biased by the choice of an arbitrary intensity threshold. Binary masks were obtained for each acquired image. Images with labeling for CGRP, IB4, gephyrin, GlyR (␣1 subunit), GABA A Rs (␣1, ␣2, ␣3, ␣5, and ␤3 subunits), ␣-DG, NL2, and CB2 were used for quantitative analysis.
For each pair of masks, the overlap pixel percentage was calculated as an index of structure colocalization. For each pair of masks, two overlap percentages were defined as the ratio of the number of pixels included in both masks to the area of each mask in the ROI as follows:
Comparison of labeling obtained with two fixation protocols. Top, Micrographs of the GABA A R ␣2 and ␣3 subunits, gephyrin, of the GlyR ␣1 subunit and of the GABA A R ␤3 subunit using a mild fixation protocol with immersion of frozen sections of fresh tissue in 4% PFA for 10 min. Bottom, Same labeling with a standard 4% PFA perfusion followed by 2 h postfixation. Identical antibody concentrations and confocal laser settings were used for images obtained with both fixation protocols. For SN, the number of clusters per 100 m 2 gives an index of the cluster detection for each marker in both fixation protocols. Values are expressed as mean Ϯ SD. Scale bar, 40 m.
This was computed for all subunits stated above with Matlab 2010a.
Results for all immunostained sections from the same rat were averaged. This technique was applied to the lamina I (LI) and LII regions in control rats. Because CGRP ϩ axonal boutons are particularly abundant in LI and For each subunit, the number of rats varied from n ϭ 5 to n ϭ 14. Scale bars, 175 m (low magnification) and 40 m (high magnification).
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Figure 3. Examples of the multiple labelings used in the study. Stainings for CGRP or IB4 (afferent terminals) combined with the GlyR ␣1 subunit (A1, A2), gephyrin (B1, B2), KCC2 (C1, C2), GABA A R ␣1 (D1, D2 ), or GABA A R ␣2 (E1, E2) subunits. Scale bar, 40 m.
IB4
ϩ boutons in LII, colocalization of each receptor subunit with CGRP was studied in LI and with IB4 in LII.
We used signal-to-noise ratio (SN) calculations to quantitatively describe the specificity of the immunostainings with the two types of fixation used here ("strong" vs "mild"). The SN was defined as the difference between the mean intensity in the mask region (signal) and outside of the mask (background noise) divided by the SD of the background region as follows:
In parallel, we also quantified the number of clusters in the ROIs. The number of distinct PSF-scale structures per unit area of mask was quantified to give an index of the immunodetection sensitivity between the two types of fixation.
To test the statistical significance of staining overlap (using GraphPad Prism 6), we compared the overlap of two masks with the same area as M1 and M2, but with pixels randomly distributed in the ROI. In an ROI with N pixels, containing a subset nG of green pixels and from which a random sample of nR (red) pixels is drawn, the probability of obtaining nGR yellow pixels is given by the hypergeometric distribution (Costes et al., 2004; Béïque et al., 2011; Mesnage et al., 2011) . In our case, N ϭ Area(ROI), nG ϭ Area(M1), and nR ϭ Area(M2). The expected number of randomly overlapping pixels is the mean of the hypergeometric distribution, nG•nR/N. To test for a significant overlap, we calculated the probability of obtaining Area(M1പM2) Ն nG•nR/N. The expected percentage area of (1) containing (2) according to this distribution therefore corresponds to:
For each marker, we obtained "observed ( y-axis)" and "expected overlaps (x-axis)" from five to 14 animals (using, on average, five histological sections in each animal). Data were plotted in graphics using the OriginPro 8 software. qRT-PCR mRNA extraction and cDNA preparation. TRIzol reagent (Invitrogen) was used to isolate total RNA from tissues. Briefly, 1 ml of TRIzol reagent was added per 50 -100 mg of tissue sample. Then tissue was homogenized with a power homogenizer. The homogenized samples were incubated for 5 min at room temperature and then 0.2 ml of chloroform per 1 ml of TRIzol reagent was added. Tubes were shaken vigorously by hand for 15 s and incubated for 2-3 min at room temperature. Samples were centrifuged at 12,000 ϫ g for 15 min at 4°C. The aqueous phase (upper layer) of the sample was transferred to a new tube and 0.5 ml of 100% isopropanol was added per 1 ml of TRIzol reagent used for homogenization. Samples were incubated at room temperature for 10 min and then centrifuged at 12,000 ϫ g for 10 min at 4°C. Supernatants were removed from the tubes and pellets were washed with 1 ml of 75% ethanol per 1 ml of TRIzol reagent. Samples were centrifuged at 7500 ϫ g for 5 min at 4°C. Ethanol was discarded and the RNA pellet was air dried. To measure the concentration of RNA, the RNA pellet was dissolved with DEPC H 2 O. Then, 1 g of total RNA was reverse transcribed into cDNA by SuperScript III Reverse Transcriptase (Invitrogen). Oligo (dT) 18 was used as a primer. cDNA quantification. We quantified the relative expression of the following genes: Gabra1, Gabra2, Gabra3, GPHN (gephyrin), DAG1 (␣-DG), NLGN2 (NL2), and ARHGEF9 (CB2) as a function of the expression of the reference housekeeping gene TFRC (Rat Transferrin Receptor). qRT-PCRs were run in various tissues: DRG, spinal dorsal horn and brain, liver, or spleen tissue was chosen as negative control. Liver tissue was used as a control for the study of Gabra1, Gabra2, and Gabra3 mRNAs. The spleen was preferred to the liver as a negative control for GPHN because gephyrin is highly expressed in the liver compared with the spleen (Ramming et al., 2000) . Gephyrin enzymatic activity is required in the liver, explaining the high level of expression in this tissue. For this reason, the spleen was chosen as a tissue control for the other GABA A R-associated proteins, DAG1, NLGN2, and AR-HGEF9. Real-time quantitative PCRs were performed with an equal amount of cDNA in the LightCycler 480 system (Roche) using LightCycler 480 SYBR Green I Master (Roche). Reactions (total 20 l) were incubated at 95°C for 5 min, followed by 45 cycles of 30 s at 95°C and 30 s at 58°C, followed by 1 min at 72°C. Water controls and a negative control containing no reverse transcriptase were included to ensure specificity. Primer efficiencies in each tissue and each experiment were integrated into the calculation of the final target/ reference gene mRNA ratio using the LC480 converter and LinRegPCR software. All PCR primers are listed in Table 3 Multiple t test comparisons using the Holm-Sidak post hoc method (GraphPad Prism 6) were used for the statistical data analysis of the qRT-PCR results.
A1 B1
A2 B2
A3 B3
A4 B4 Figure 4 . Illustration of the method of colocalization analysis used in this study. A1, A2, Confocal images of stainings for GAD65 and IB4, known not to be colocalized. A3, Two binary masks derived from the two stainings. On the graph in A4, each point indicates the ratio value of observed versus expected overlap between the two masks for each rat (n ϭ 8 rats). The dotted line represents the relationship for a purely random distribution of the two staining. The values obtained were not significantly higher than that expected from random distributions. B1, B4, Same type of analysis for CGRPandIB4labelings,whichareknowntobecolocalizeinasmallnumberofprimaryafferents.Both labels showed observed respective overlaps that were significantly higher than expected from random distributions (n ϭ 12 rats). ***p Ͻ 0.001. Scale bars: A1, B1, 175 m; A2-B3, 5 m.
Results
Comparison of fixation protocols
To study the subcellular distribution of GABA A Rs and its relationship to the anchoring protein gephyrin, we needed an immunostaining approach that would optimally reflect the natural synaptic distribution of the receptors. This is complicated by the fact that immunodetection of GABA A R receptors can be strongly affected by fixation (Schneider Gasser et al., 2006; . We thus first conducted a comparison of staining obtained with mild and regular fixation protocols (Fig. 1) . Standard fixation was obtained using a perfusion protocol and mild fixation was achieved with on-slide postfixation for controlled short periods of time (see Materials and Methods). The two types of fixation provided comparable results for CGRP and IB4 labeling. In contrast, GABA A R, GlyR, and gephyrin immunodetection appeared sensitive to fixation, not only in signal strength (SN; Fig. 1 ), but also in the number of synaptic clusters detected per 100 m 2 . In addition, with the perfusion fixation, random artifacts (unspecific labeling of glial cells) appeared for GlyR ␣1 and GABA A R ␣2 and ␣3 subunit immunolabeling (Fig. 1) as described previously (Schneider Gasser et al., 2006; . The global intensity of gephyrin staining, as well as the number of clusters, strongly decreased in all samples with perfusion fixation, but no apparent ectopic labeling was detected (Fig. 1) . For the GABA A R ␤3 subunit, the staining with perfusion fixation yielded comparable detection of clusters (15.3 Ϯ 0.9/100 m 2 vs 17.6 Ϯ 0.5/100 m 2 ). Consistent with this observation, it appeared insensitive to fixation conditions (comparable SNs: 2.27 Ϯ 01.8 vs 2.24 Ϯ 0.13; Fig. 1 ) in contrast to the ␣-subunit immunostaining. Mildly fixed spinal cord sections were also devoid of artifacts and yielded convincing clustered labeling for all of the ␣ subunits, characteristic of the GABA A R distribution reported in the literature (Bohlhalter et al., 1994; Bohlhalter et al., 1996; Schneider Gasser et al., 2006 ; Fig. 1 ). For gephyrin, the GlyR ␣1 subunit, and the GABA A R ␣2/␣3 subunits, the immunofluorescence signal was less diffuse and more intense with the mild fixation (Fig. 1) . Therefore, the number of clusters detectable by this method of fixation was higher. For further quantification and to identify labeling in primary sensory terminals, we used the mild fixation protocol.
A B Figure 5 . Confirmation of the reliability of the colocalization analysis. Colocalization analysis as in Figure 4 (see also Materials and Methods) applied to labeling for KCC2 (A), known not to be expressed in primary afferents (Coull et al., 2003) and to labeling for GlyR ␣1 (B), known to highly associate with gephyrin clusters. ****p Ͻ 0.0001. For each marker, the numbers of rats were as follows: n ϭ 6 for KCC2/CGRP, n ϭ 12 for KCC2/IB4, and n ϭ 10 for GlyR ␣1/gephyrin in LI and LII. Scale bar, 5 m.
A B Figure 6 . The glycine receptor ␣1 subunit and gephyrin clusters were not found in nociceptive primary afferents terminals. A, B, Colocalization analysis for either the GlyR ␣1 subunit (A) or its anchoring protein gephyrin with either CGRP or IB4 labeling (B). For each marker, the numbers of rats were as follows: n ϭ 5 for GlyR ␣1/CGRP, n ϭ 7 rats for GlyR ␣1/IB4, n ϭ 5 for gephyrin/ CGRP, and n ϭ 12 rats for gephyrin/IB4. Scale bar, 5 m.
Laminar distribution of immunostaining
To establish a reference baseline for analysis of the distribution of GABA A Rs and GlyRs, as well as of their main anchoring protein gephyrin in small diameter primary afferent terminals, we first assessed their relative expression in LI and LII of the dorsal horn, which represent the main layers where these primary afferents terminate (Fig. 2) . Concerning GABA A Rs, we focused on the benzodiazepine-sensitive ␣ subunits (␣1, 2, 3 and 5) and the most ubiquitous ␤3 subunit because these are the ones that have been shown to be present in the spinal dorsal horn (Bohlhalter et al., 1994; Alvarez et al., 1996; Bohlhalter et al., 1996; McKernan and Whiting, 1996) . We also focused on the ␣1 subunit of the GlyR because it is the ubiquitous subunit in adult tissue . Figure 2 , A-D, shows representative distribution patterns for selected subunits across the superficial laminae. Laminar limits were assessed on the basis of previously established criteria: distance from the white matter and distribution of IB4 staining in LII (Lorenzo et al., 2008) .
To perform a quantitative analysis of the relative receptor and anchoring protein expression between the two superficial laminae, LI and LII, we used two parameters: mean intensity and area occupied by the staining. Area was defined using a binary mask as described in the Materials and Methods. Data were reported as the LI/LII ratio for each of these two parameters (Fig. 2E) . We found that both mean intensity and area of the staining were significantly higher in LII for all markers studied (Fig. 2E) . However, this asymmetry was significantly smaller for the GABA A R ␣2 and ␣3 subunits (0.05 Ͻ p Ͻ 0.001; Fig. 2E ). These findings raise the question of whether these inhibitory markers are preferentially distributed on nonpeptidergic (IB4 ϩ ) afferent terminals, which predominate in LII, and not on the peptidergic (CGRP ϩ ) terminals, which predominate in LI and the outer LII (LIIo).
Quantitative analysis protocol to test for localization of inhibitory synaptic markers in primary afferent terminals
We then performed multiple labelings to measure the level of expression of inhibitory synaptic markers in defined cellular compartments. Cellular compartments studied included peptidergic (CGRP ϩ ) and nonpeptidergic (IB4 ϩ ) small afferent terminals, as well as inhibitory postsynaptic sites (gephyrinϩ; Figs. 3, 4) .
Determining whether a signal of interest is located within subcellular compartments that have dimensions on the order or smaller than that of the PSF is a challenge because the incidence of falsepositives (apparent colocalization) can be high. This is especially important considering that the confocal PSF in the axial direction is significantly (typically Ͼ3-fold) larger than in the transverse axis (Cole et al., 2011) . The probability of detecting false-positives is proportional to the relative area of an image occupied by each maker. We thus used a quantification approach that takes this into consideration (see Materials and Methods). Briefly, after binarization of the image to define the areas occupied by each of the markers studied, we computed an overlap pixel percentage as an index of structure colocalization (ratio of the number of pixels included in both masks to the area of each mask in a ROI). Colocalization was considered as occurring if the observed degree of pixel overlap significantly exceeded that expected from a randomly overlapping pixels given a hypergeometric distribution (see Materials and Methods).
To test the validity of this approach, we applied it to known paradigms of signal colocalization and separation. First, we studied markers of two structures known to be completely separated, but frequently apposed onto one another (Barber et al., 1978; Ma and Ribeiro-da-Silva, 1995; Mackie et al., 2003) . For that, we used anti-GAD65 immunostaining to label inhibitory boutons and IB4 binding to label nonpeptidergic small afferent terminals (Fig.  4A) . Analysis of labeling for these two markers revealed that the percentage of observed overlap was not significantly higher than that expected from a random distribution between the two stainings, given the relative proportion of the image they occupy (11.9 Ϯ 0.5% vs 12.3 Ϯ 0.4%; p ϭ 0.35; n ϭ 8 rats; Fig. 4A4 ). The second approach we used was to study markers that occur mostly on separate populations of primary afferents (Murinson et al., 2005) but are known to colocalize in a small subpopulation of them. For that we used CGRP ϩ and IB4 ϩ terminals ( Fig. 4B ; Wang et al., 1994; Price and Flores, 2007; Lorenzo et al., 2008) . In the case of CGRP and IB4 colabeling, the observed pixel overlap (percentage of IB4 staining within the CGRP mask and percentage of CGRP labeling in IB4 mask in LII) was 23.8 Ϯ 1.9% and A B Figure 7 . The ␣1 subunit of the GABA A receptor is absent from small diameter nociceptive primary afferent terminals. A, B, Top, Sets of micrographs representing triple staining for CGRP/gephyrin/GABA A R ␣1 subunit. Bottom, Sets of micrographs representing examples of binarized masked extracted from the confocal images above. The bottom graphs represent the colocalization analysis of observed values versus those expected from random distributions of each label. The numbers of rats for each colocalization were as follows: n ϭ 6 for GABA A R ␣1/CGRP, n ϭ 6 for ␣1/IB4, and n ϭ 12 for GABA A R ␣1/gephyrin in LI and LII. ****p Ͻ 0.0001. Scale bar, 5 m.
22.6 Ϯ 1.4%, respectively, significantly higher than that expected from random apparent colocalizations (8.3 Ϯ 0.4%, p Ͻ 0.0001, and 10.7 Ϯ 0.6%, p Ͻ 0.001; n ϭ 12 rats). The observed level of colocalization was comparable to that reported in the literature (Wang et al., 1994; Sakamoto et al., 1999; Price and Flores, 2007; Lorenzo et al., 2008) . A third test paradigm was the use of KCC2 labeling, which is known to be absent from DRGs and synaptic terminals (Coull et al., 2003) . Colabeling for KCC2 and CGRP or IB4 revealed no significant colocalization (Fig. 5A) . In fact, in contrast to GAD65 immunostaining, the observed percentage of pixel overlap for KCC2 staining appeared lower than expected for IB4 labeling ( p Ͻ 0.001), suggesting that KCC2 is localized away from IB4 afferents. This is consistent with the studies showing that KCC2 is distributed evenly throughout the somatodentritic regions of neurons (Doyon et al., 2011) and absent from synaptic terminals (Coull et al., 2003) , in contrast to GAD65, which occurs in terminals, a significant proportion of which is known to be apposed to primary afferents (Barber et al., 1978; Mackie et al., 2003) .
The final test we conducted was for GlyR versus gephyrin staining, because GlyRs are known to be preferentially associated with gephyrin clusters. The analysis revealed that the observed pixel overlap between GlyR ␣1 subunit labeling and gephyrin labeling was significantly higher than that expected from a random distribution in both LI and LII, regardless of the fact that gephyrin labeling occupied a much lower proportion of LI than of LII ( p Ͻ 0.0001; Fig. 5B ), consistent with previous reports (Ehrensperger et al., 2007) .
These test paradigms show conclusively that the approach was sufficiently discriminative to test robustly for the expression of different inhibitory synaptic markers in small afferent terminals using a conventional CLSM technique.
Lack of GlyR and gephyrin clusters in small diameter afferent terminals
Whereas the presence of GlyR and gephyrin is undeniable in the spinal dorsal horn, the question has long remained of whether they are significantly expressed on terminals of small diameter primary afferents. To address this, we performed double and triple labelings combining markers of primary afferents (CGRP or IB4), of GlyR ␣1 subunits, and of gephyrin. In contrast to findings of colocalization within gephyrin clusters (Fig. 5B) , GlyR ␣1 subunits were not colocalized with the marker of peptidergic afferent terminals (CGRP) nor with the marker of nonpeptidergic terminals (IB4; Fig. 6A ). Consistent with this finding, there was no evidence of any significant presence of gephyrin labeling within these primary afferent terminals (Fig. 6B) . This indicates that glycine does not contribute to presynaptic inhibition of small diameter primary afferent input to the dorsal horn. This observation is consistent with the lack of effect of glycine receptors on primary afferent depolarization (Jiménez et al., 1987; Willis and Coggeshall, 1991; Engelman and MacDermott, 2004; Zeilhofer et al., 2012) . Only expression of the ␤ subunit of the GlyR has been reported in DRG neurons (Furuyama et al., 1992) .
Relative expression of GABA A R subunits in small diameter primary afferent terminals versus superficial dorsal horn neurons Because gephyrin was not found in primary afferents of LI and LII, we could use it as a tool to differentiate expression of GABA A Rs in terminals of nociceptive primary afferent terminals versus dorsal horn neurons in LI and LII. Previous studies have provided evidence of GABA A R mRNA in DRG neurons (Persohn et al., 1991; Furuyama et al., 1992; Ma et al., 1993; Maddox et al., 2004) in rats and humans and of the presence of certain GABA A R subunits in mouse small diameter primary afferent terminals (Witschi et al., 2011; Paul et al., 2012) . However, a thorough quantitative assessment of relative distribution of each subunit in small diameter primary afferent terminals is lacking, especially in rats. Similar analyses to those described in the previous section were performed for all GABA A R benzodiazepine-sensitive subunits (Figs. 7, 8, 9 ). In addition to colocalization with CGRP and IB4, their colocalization with gephyrin was also assessed using triple stainings as a confirmation of the reliability of this approach (Figs. 7, 8, 9 ). The GABA A R ␣1 subunit was not found significantly in peptidergic CGRP ϩ afferents nor on nonpeptidergic IB4
ϩ terminals (Figs. 3D2, 7A ). In contrast, this subunit A B Figure 8 . Expression of the GABA A R ␣2 subunit in small diameter nociceptive primary afferent terminals. A, B, Triple staining of IB4/gephyrin/GABA A R ␣2 subunit. The bottom panels of each set or micrographs represent examples of binarized masked extracted from the confocal images above. The bottom graphs represent the colocalization analysis of observed values versus those expected from random distributions of each label. The numbers of rats used for each colocalization were as follows: n ϭ 11 for GABA A R ␣2/CGRP, n ϭ 14 for ␣2/IB4, and n ϭ 14 for GABA A R ␣2/gephyrin in LI and LII. *p Ͻ 0.05; ***p Ͻ 0.001; ****p Ͻ 0.0001. Scale bar, 5 m.
was significantly located in association with gephyrin clusters ( p Ͻ 0.001 in LI; p Ͻ 0.0001 in LII; Fig. 7B ). In contrast, the GABA A R ␣2 subunit was found significantly in both CGRP ϩ and IB4 ϩ terminals ( p Ͻ 0.0001; Fig. 8A ). Interestingly, the density of this subunit was significantly higher in the IB4 ϩ terminals than in the CGRP ϩ terminals ( p Ͻ 0.001; Fig. 8B ). As for the ␣1 subunit, the GABA A R ␣2 subunit was also localized significantly in gephyrin clusters ( p Ͻ 0.01 in LI; p Ͻ 0.0001 in LII), possibly because of a direct binding between these subunits and gephyrin (Tretter et al., 2008; Mukherjee et al., 2011) . Finally, the remainder of the GABA A R subunits studied, ␣3, ␣5, and ␤3, were significantly expressed in small afferent terminals and in gephyrin clusters, with the exception that the ␣5 subunit was neither significantly expressed in CGRP ϩ terminals nor in gephyrin clusters within LII (Fig. 9A-F ) .
Combining gephyrin staining as a marker of postsynaptic sites with CGRP or IB4 labeling for small diameter afferent terminals, we performed a quantitative assessment of the relative presynaptic versus postsynaptic distribution of the GABA A R subunits. We found that they were preferentially expressed postsynaptically in LI-LIIo, where CGRP ϩ terminals are particularly abundant (Fig. 10A) . In contrast, in LII, where IB4 ϩ terminals are more abundant, only the ␣1 GABA A R subunit was significantly more expressed postsynatically (Fig. 10B) . In LII, the expression of the ␣2 and ␣5 GABA A R subunits was significantly more important on IB4 ϩ primary afferents, whereas the presence of the ␣3 and ␤3 GABA A R subunits was more balanced between presynaptic and postsynaptic sites. Therefore, whereas in LI, GABA A Rs appear to be relatively more postsynaptically located, in LII, a more balanced presynaptic and postsynaptic distribution occurs.
Electron microscopy revealed the presence of the GABA A receptor ␤3 subunit in the central boutons of type Ia and type IIa synaptic glomeruli Finally, we wanted to confirm, at the ultrastructural level, the presence of GABA A Rs and their relationship to inhibitory synapses on small diameter primary afferent terminals. To achieve this, we used labeling for the ␤3 subunit because it is more ubiquitously expressed in GABA A Rs (Alvarez et al., 1996) and because staining for this subunit was more resistant to fixation (Fig. 1) , allowing us to use a fixation protocol compatible with electron microscopy.
We used a combination of preembedding immunogold to detect the ␤3 subunit with DAB-based immunocytochemistry to detect GAD65 ϩ inhibitory synaptic terminals. We found the ␤3 GABA A Rs in the central boutons of type Ia synaptic glomeruli (Fig. 11A-C) , which are known to represent terminals of small diameter nonpeptidergic afferents (for description of synaptic glomeruli, see Ribeiro-da-Silva, 2004; Ribeiroda-Silva and De Koninck, 2008) . We also found the ␤3 subunit in the larger and lighter terminals of type II glomeruli (i.e., type IIa; Fig.  11D ,E), which represent likely nonnociceptive myelinated afferents. The central boutons, which were positive for ␤3 GABA A Rs, were apposed by GAD65 ϩ boutons (Fig. 11A-E) . However, the labeling did not appear to be particularly clustered at the postsynaptic site opposite to GAD65 ϩ boutons, in contrast to the obvious alignment of the silver-gold grains at the level of the postsynaptic thickening in axo-dendritic and axosomatic synapses (Fig. 11F-H) .
Other presynaptic GABA A R-associated proteins Because gephyrin clusters were absent from small diameter afferent terminals, we decided to test for the presence of other GABA A R-associated proteins Tretter et al., 2012; Tyagarajan and Fritschy, 2014) . In the hippocampus and thalamus, postsynaptic NL2 appears to be associated with gephyrin via its intracellular domain and to presynaptic ␣/␤-Neurexin via its extracellular domain (Fritschy et al., 2012; Tyagarajan and Fritschy, 2014). This complex may be associated with the ␣-DG/ A B C D E F Figure 9 . Expression of ␣3, ␣5, and ␤3 subunits of the GABA A receptor in nociceptive afferent terminals and inhibitory postsynaptic sites. Shown is the analysis of colocalization of the ␣3 subunit with CGRP/IB4 (respectively, n ϭ 6 and 8 rats; A), or gephyrin (n ϭ 6 in LI and 5 rats in LII; B), the ␣5 subunit with either CGRP/IB4 (n ϭ 5 and 7 rats; C), or gephyrin (n ϭ 5 in LI and 6 rats in LII; D), the ␤3 subunit with CGRP/IB4 (n ϭ 6 and 9 rats; E), or gephyrin (n ϭ 14 rats in LI and LII; F ). *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001; ****p Ͻ 0.0001.
␤-DG and sometimes with CB2 (Gee et al., 1994; Montanaro and Carbonetto, 2003; Renner et al., 2008; . The stainings obtained for DG, NL2, and CB2 in the rat spinal dorsal horn are illustrated in Figure 12 , A-C. We found that DG and NL2 were expressed in both CGRP ϩ and IB4 ϩ terminals (0.0001 Ͻ p Ͻ 0.01; Fig. 12 D, E) , whereas CB2 was exclusively found in CGRP ϩ terminals ( p Ͻ 0.01; Fig. 12F ). On the postsynaptic side, in the dorsal horn, only NL2 was found within gephyrin clusters (11 Ϯ 0.7% in LI; 14.8 Ϯ 1.8% in LII, p Ͻ 0.0001; Fig. 12H ). In contrast, gephyrin ϩ synapses in the dorsal horn were devoid of DG (Fig. 12G) and CB2 (Fig. 12I ) . On the presynaptic side, GABA A R ␤3 subunits were associated with DG within the CGRP ϩ and the IB4 ϩ terminals (5.4 Ϯ 0.8% in CGRP and 6.8 Ϯ 0.8% in IB4, p Ͻ 0.01; Fig. 12J ). GABA A R ␣2 subunits were also associated with presynaptic afferent terminals positive for DG (5.3 Ϯ 0.2%, p Ͻ 0.01; Fig. 12K ).
Quantification of mRNA encoding GABA A R subunits and associated proteins
To compare protein expression detected by immunocytochemistry with their corresponding mRNA expression, we used qRT-PCR to measure the relative expression of Gabra1, Gabra2, Gabra3, GPHN, DAG1 (DG), NLGN2, and ARHGEF9 (CB2) mRNAs as a function of the expression of the housekeeping gene TFRC. qRT-PCRs were run in various tissues, including the DRG, spinal dorsal horn, brain, liver, and spleen. Liver and spleen were chosen as negative controls (see Materials and Methods). Consistent with previous reports (Whiting et al., 1999) , we found that the brain was the tissue expressing the maximal level of Gabra1 (Fig. 13A) . In contrast, we found no significant Gabra1 expression in the DRG (Fig. 13A) . Contrary to Gabra1, Gabra2 was the most expressed Gabra subunit in DRG (Fig. 13A) and was also well expressed in the spinal dorsal horn and brain (Fig. 13A) . Gabra3 was also significantly expressed in the DRG (Fig. 13A) , even though the gene was more expressed in the spinal dorsal horn (Fig. 13A) . Our qRT-PCR results confirmed our immunocytochemical analysis revealing no GPHN expressed in DRGs. In contrast, GPHN was significantly expressed in the spinal dorsal horn and the brain (Fig. 13B) . Contrary to GPHN, DAG1 was significantly expressed in DRGs, where we found its highest expression level (Fig. 13C) . Finally, NLGN2 and ARHGEF9 were also significantly expressed in DRGs, the spinal dorsal horn, and the brain (Fig. 13 D, E) .
Discussion
The main findings of this study were as follows: (1) both CGRP ϩ (peptidergic) and IB4 ϩ (nonpeptidergic) small afferent terminals were devoid of GlyR ␣1 subunit and of the anchoring protein gephyrin; (2) other GABA A R-associated proteins-␣-DG, NL2, and CB2-were expressed in small afferent terminals; (3) the ␣2, ␣3, ␣5, and ␤3 subunits, but not the ␣1 subunit, of GABA A Rs were expressed on small diameter afferent terminals, with preferential distribution on nonpertidergic terminals; and (4) all GABA A Rs tested were preferentially postsynaptic in spinal LI, whereas the ␣2 and ␣5 subunits were preferentially presynaptic in LII.
Conclusive demonstration of the lack of GlyR ␣1 subunit and gephyrin on terminals of small diameter afferents and the presence of GABA A Rs and other GABA A R-associated proteins on these terminals was made possible thanks to the combination of two strategies. The first one was the use of a mild fixation protocol that was optimized to reveal GABA A Rs, GlyRs, and other GABA A R-associated proteins (Schneider Gasser et al., 2006; . The second was the use of a quantitative analysis strategy of confocal images that allowed us to rule out falsepositive detection of colocalization. Indeed, we considered that two proteins were significantly colocalized only when the amount of overlapping pixel was exceeding what can be expected from randomly overlapping pixels based on the relative proportion of the pictures occupied by each of the signals detected.
Mild fixation protocol is crucial for immunodetection of some antigens
It is important to emphasize the importance of the fixation protocols on the specificity of the immunostainings of gephyrin, the GlyR and GABA A R subunits, and their associated proteins. Indeed, tissue fixation and processing can have a strong impact on antigenicity by producing conformational changes of the epitopes, limiting their accessibility (epitope masking) and decreasing immunodetection (Bohlhalter et al., 1994; Bohlhalter et al., 1996; Schneider Gasser et al., 2006) . Some fixation approaches translate into lower SNs and less antigenic site detection. Inappropriate fixation protocols can even generate high, nonspecific background (Schneider Gasser et al., 2006; . Many of these differences have been studied and compared using wild-type and KO mice. For example, in a previous report, such data and their pitfalls were illustrated for the GABA A R ␣3 subunit . Therefore, we deemed it important to compare fixation protocols in the present study. In particular, we found that the SN of our immunostaining and the cluster detection provided an objective, quantitative assessment of the quality of the immunolabeling. It nevertheless remains that one cannot definitely rule out the presence of a protein from the absence of an antibody labeling due to inherent detection limits. This is why we sought to confirm our immunolabelings in sensory terminals with complementary qRT-PCR analysis from the DRG.
Absence of gephyrin and GlyR clusters in small diameter afferent terminals
We did not find any evidence of the occurrence of gephyrin clusters in small diameter primary afferent terminals in the dorsal horn. However, low levels of gephyrin mRNA and protein have been reported in DRG lysates (Paul et al., 2012) . However, in our study, we referenced our measurement to that made in tissues previously shown to lack GPHN (Ramming et al., 2000) . Under those conditions, our results show that GPHN detection was not significantly different from that in negative reference tissue. It is therefore possible that the levels of GPHN detection previously reported reflected background detection by the PCR primers. In any case, detection of mRNAs or proteins in DRGs is not absolute proof of the presence of the protein in terminals in the dorsal horn. Moreover, in addition to containing neurons, whole DRG lysates also contain glial cells that can be positive for markers of inhibitory neurotransmission (Müller et al., 1994; Bhat et al., 2010; Lee et al., 2011) .
Our results are consistent with previous ultrastructural findings. Indeed, electron microscopic studies revealed the absence of gephyrin immunolabeling in central axonal boutons of type II glomeruli (Mitchell et al., 1993; , whereas gephyrin immunogold particles were clearly visible postsynaptically in neighboring dendrites (Mitchell et al., 1993) . Whereas failure to detect gephyrin in the previous study could have been ascribed to reduce gephyrin immunoreactivity from the strong fixation protocol used, our study using a mild fixation protocol confirmed the previous observations (Mitchell et al., 1993) . Whereas our light microscopy approach had lower resolution than an EM analysis, our analytical algorithm prevented false-positive codetection when studying subdiffraction limited structures. It nevertheless remains possible that gephyrin is still present at very low levels in these afferents under nonclustered form. However, based on the above, we propose that, in the superficial dorsal horn, gephyrin clusters can be used as reliable markers of inhibitory postsynaptic sites.
Interestingly, in contrast to GPHN, we found significant levels of expression of three important GABA A R-associated proteins: DAG1, NLGN2, and ARHGEF9. Past data had shown that DG clustering can occur independently of gephyrin clustering in GPHN KO mice (Feng et al., 1998; Lévi et al., 2002) . Our present results suggest a differential inhibitory synaptic arrangement between dorsal horn neurons and afferent terminals, suggesting an "atypical" inhibitory synaptic structure in sensory terminals compared with other central inhibitory synaptic organizations. Consistent with the absence of gephyrin clusters, we did not find any evidence of the presence of GlyR ␣1 subunit in primary afferent terminals in the dorsal horn. Again, this was in contrast to previous reports of mRNA for the ␤ subunit of GlyRs in DRG neurons (Furuyama et al., 1992) . The lack of ␣1 subunit in the terminals argues against functional GlyR-mediated presynaptic inhibition of these afferents. The alternate ␣3 GlyR subunit was found to be 100% localized in gephyrin clusters in the superficial dorsal horn (Harvey et al., 2004; , which, together with our finding that gephyrin clusters are exclusively postsynaptic, indicates that this subunit also does not occur in small diameter primary afferent terminals. It thus appears that glycine is not involved in presynaptic inhibition of these afferents in the spinal dorsal horn, consistent with previous physiological reports ( Jiménez et al., 1987; Willis, 2006 ). There appears to be an "anti-correlation" between the distribution of IB4 and KCC2 profiles, in contrast to CGRP versus KCC2 or IB4 versus GAD65. When profiles do not colocalize but are nevertheless in close apposition to one another (such as GAD65 ϩ and IB4 ϩ profiles), our colocalization analysis showed that the observed distribution was not different from that expected of a random overlap. However, our analysis revealed a systematic "less than expected" overlap between IB4 and KCC2 profiles. This may suggest that IB4 terminals specifically avoid KCC2-positive structures. Further experiments are required to confirm such inference.
Expression of GABA A R subunits in small diameter primary afferent terminals Regarding the composition in GABA A R on the two populations of primary afferents we studied, we found that the GABA A R ␣1 subunit was absent from primary afferents, indicating that this subunit is not involved in presynaptic inhibition of these afferents. Consistent with our finding, the Gabra1 mRNA was selectively absent from rat and human DRGs (Persohn et al., 1991; Ma et al., 1993; Maddox et al., 2004) and there was a lack of staining for this subunit in mouse primary afferent terminals (Paul et al., 2012) . In contrast, we found that the GABA A R ␣1 subunit was significantly expressed in gephyrin clusters, indicating a contribution of this subunit to postsynaptic inhibition in LI and LII. The finding of an absence of ␣1 GABA A R subunits in small diameter nociceptive afferent terminals is particularly important because GABA A Rs possessing this subunit are known to mediate sedation, at least in mice and humans McKernan et al., 2000; Rudolph and Möhler, 2006) . In contrast, we have found that the ␣2 GABA A R subunit was significantly expressed in small diameter primary afferent terminals, although substantially more on nonpeptidergic than on peptidergic terminals. Although nonpeptidergic C nociceptors are known to receive axoaxonic synapses from GABAergic neurons, these syn-
A1
A2 A3 B C D E Figure 13 . qRT-PCR of mRNAs encoding ␣1, ␣2, and ␣3 GABA A R subunits and associated proteins. qRT-PCR of Gabra1 (A1), Gabra2 (A2), and Gabra3 (A3) in the liver (control), the DRG, the spinal dorsal horn (DH), and the brain. B, qRT-PCR of GPHN. C-E, qRT-PCR of mRNA encoding for other GABA A R-associated proteins, C, DAG1 (␣-DG), D, NLGN2 (NL2), and E, ARHGEF9 (CB2), in the spleen (control), the DRG, the spinal dorsal horn and the brain. Numbers of rats were as follows: for liver, n ϭ 3; for spleen, n ϭ 4; for DRG, n ϭ 4; for spinal DH, n ϭ 4; and for brain, n ϭ 7. For every tissue, we used the same number of animals in all experiments. Øp Ͼ 0.05; *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001.
apses are rarely seen on peptidergic afferents Ribeiro-da-Silva and De Koninck, 2008) . This would suggest that any activation of these receptors would be nonsynaptic. Furthermore, the ␣2 GABA A R and ␣5 GABA A R subunits were mainly located presynaptically in nonpeptidergic afferents of LII, consistent with its association with IB4 ϩ terminals (Xiao et al., 2002 ) and in contrast to ␣3 subunits, which had a more balanced presynaptic and postsynaptic distribution. These findings are consistent with evidence of a major role of ␣2 subunits in presynaptic inhibition of nociceptive afferents in rats (Persohn et al., 1991) or mice (Witschi et al., 2011) . A gephyrin-independent clustering of the ␣2 GABA A R had already been reported in hippocampal neurons lacking gephyrin from KO mice (Lévi et al., 2004) . This finding is of particular interest in light of our observation of ␣2 GABA A R enrichment in afferent terminals in the absence of gephyrin. Sensory afferents may thus constitute a natural gephyrin-deficient system with which to study gephyrin-free GABA A R-mediated inhibition.
In contrast to other subunits, the ␣5 GABA A R subunit was present at low levels in gephyrin clusters. This is consistent with the general finding that this subunit is mainly expressed extrasynaptically, contributing to tonic inhibition (Takahashi et al., 2006) .
Conclusion
Our results, together with previous findings, indicate that ionotropic presynaptic inhibition in small diameter afferents appear to be exclusively GABA A R mediated. However, the lack of gephyrin clusters in these nociceptive fiber terminals also indicates that the GABA A Rs localized in them are not anchored by gephyrin. Gephyrin-independent GABA A R clustering has been observed in different systems (Kneussel et al., 2001; Niwa et al., 2012; Tretter et al., 2012) . However, our ultrastructural analysis suggests a lack of apparent GABA A R clustering at presynaptic sites (i.e., in afferent terminals), in contrast to postsynaptic sites (i.e., on dorsal horn neurons). The anchoring of GABA A Rs may thus follow different rules at presynaptic and postsynaptic levels in the dorsal horn. Nonclustered distribution of GABA A Rs on afferent terminals may suggest a more diffuse mode of inhibition at these inhibitory synapses, consistent with the characteristically much slower time course of GABA A R-mediated presynaptic inhibition (primary afferent depolarization) than its postsynaptic counterpart (De Koninck and Henry, 1994) . In addition, our study may also open avenues to better distinguish presynaptic from postsynaptic actions of newly designed therapeutic agents, in particular, by providing clues to better differentiate the presynaptic from the postsynaptic effects of novel GABA A receptor subtype-specific benzodiazepines (Munro et al., 2013; McCarson and Enna, 2014) .
